You could be based in a pharmaceutical company, working on trialing new drugs; or in a public-sector research center, helping to ensure national healthcare provision keeps pace with new discoveries. Category: Benzisoxazole.
Oral zonisamide (Zonegran(A (R))) is a benzisoxazole derivative chemically unrelated to other antiepileptic drugs (AEDs). It is approved in the EU as an adjunct to other AEDs in the treatment of pediatric patients aged a parts per thousand yen6 years with partial seizures, with or without secondary generalization. In a randomized, double-blind, multinational, phase III study in pediatric patients aged 6-17 years with partial seizures, the proportion of patients achieving a a parts per thousand yen50 % reduction from baseline in seizure frequency per 28 days during the maintenance treatment period was significantly higher with adjunctive therapy with zonisamide than placebo. The antiepileptic efficacy of zonisamide was sustained during a 59-week extension study in this patient population. Zonisamide was generally well tolerated in these studies, with the majority of adverse events being mild or moderate in severity. Thus, oral zonisamide as an adjunctive therapy to other AEDs provides a useful option in the treatment of pediatric patients aged a parts per thousand yen6 years with partial seizures.
If you are hungry for even more, make sure to check my other article about 99-06-9, Category: Benzisoxazole.
Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics